Table 3.
Results from precipitation testing after mixing cefotaxime 40 mg/ml, dopamine 2 mg/ml, morphine 0.2 mg/ml and aqNumeta G13E + in different mixing ratios (bold font indicates values outside acceptance criteria) (average ± SD; n = 3)
| Drug | Mix ratio | Particles/ml ≥ 0.5 μm | Turbidity (FNU) | pH | |||||
|---|---|---|---|---|---|---|---|---|---|
| 0 h | 4 h | 0 h | 4 h | 0 h | 4 h | ||||
| aqNumeta G13E + | Control | 149 ± 114 | 102 ± 61 | 0.17 ± 0.06 | 0.15 ± 0.05 | 5.71 ± 0.23 | 5.72 ± 0.20 | ||
| Morphine | Control | 124 ± 78 | 78 ± 21 | 0.13 ± 0.02 | 0.14 ± 0.01 | 4.55 ± 0.18 | 4.48 ± 0.09 | ||
| Dopamine | Control | 121 ± 32 | 69 ± 29 | 0.13 ± 0.01 | 0.14 ± 0.01 | 3.84 ± 0.08 | 3.87 ± 0.09 | ||
| Cefotaxime | Control | 65 ± 23 | 93 ± 11 | 0.17 ± 0.01 | 0.17 ± 0.01 | 5.40 ± 0.06 | 5.36 ± 0.06 | ||
| Two-component analysis (drug + PN) | Morphine + aqNumeta G13E + | 1 + 1 | 696 ± 92 | 358 ± 143a | 0.14 ± 0.01 | 0.12 ± 0.01 | 5.92 ± 0.00 | 6.01 ± 0.04 | |
| 1 + 7 | 528 ± 183 | 243 ± 110 | 0.13 ± 0.02 | 0.12 ± 0.01 | 5.76 ± 0.07 | 5.69 ± 0.04 | |||
| 1 + 39 | 248 ± 82 | 282 ± 55 | 0.13 ± 0.00 | 0.12 ± 0.02 | 5.84 ± 0.01 | 5.87 ± 0.02 | |||
| Cefotaxime + aqNumeta G13E + | 1 + 1 | 135 ± 27 | 94 ± 9 | 0.30 ± 0.07 | 0.18 ± 0.02 | 5.79 ± 0.01 | 5.76 ± 0.01 | ||
| 9 + 1 | 74 ± 25 | 152 ± 26 | 0.22 ± 0.02 | 0.17 ± 0.02 | 5.77 ± 0.03 | 5.66 ± 0.03 | |||
| 1 + 20 | 191 ± 156 | 56 ± 13 | 0.15 ± 0.01 | 0.14 ± 0.04 | 5.86 ± 0.01 | 5.87 ± 0.01 | |||
| Dopamine + aqNumeta G13E + | 1 + 1 | 585 ± 236 | 401 ± 94 | 0.14 ± 0.04 | 0.12 ± 0.01 | 5.67 ± 0.01 | 5.69 ± 0.01 | ||
| 1 + 6 | 724 ± 228 | 400 ± 155 | 0.13 ± 0.02 | 0.13 ± 0.02 | 5.77 ± 0.02 | 5.78 ± 0.01 | |||
| 1 + 56 | 434 ± 97 | 252 ± 90 | 0.13 ± 0.02 | 0.13 ± 0.02 | 5.81 ± 0.01 | 5.81 ± 0.01 | |||
| Two-component analysis (drug + drug) | Cefotaxime + morphine | 1 + 1 | 38 ± 18 | 51 ± 5 | 0.14 ± 0.03 | 0.13 ± 0.04 | 5.20 ± 0.02 | 5.16 ± 0.06 | |
| 1 + 2 | 42 ± 36 | 59 ± 50 | 0.18 ± 0.04 | 0.20 ± 0.02 | 4.88 ± 0.33 | 4.90 ± 0.20 | |||
| 9 + 1 | 103 ± 32 | 190 ± 59 | 0.13 ± 0.03 | 0.14 ± 0.01 | 5.29 ± 0.01 | 5.07 ± 0.03 | |||
| Dopamine + morphine | 1 + 1 | 59 ± 68 | 88 ± 35 | 0.13 ± 0.01 | 0.13 ± 0.01 | 4.08 ± 0.02 | 4.04 ± 0.01 | ||
| 1 + 8 | 126 ± 29 | 68 ± 13 | 0.13 ± 0.01 | 0.13 ± 0.01 | 4.31 ± 0.01 | 4.29 ± 0.01 | |||
| 40 + 1 | 58 ± 21 | 113 ± 65 | 0.14 ± 0.00 | 0.14 ± 0.00 | 3.82 ± 0.04 | 3.77 ± 0.04 | |||
| Three-component analysis (drug + morphine + PN) | Dopamine + morphine + aqNumeta G13E + | 1 + 1 + 1 | 10 ± 3 | 14 ± 2 | 0.13 ± 0.01 | 0.13 ± 0.03 | 5.87 ± 0.03 | 5.95 ± 0.01 | |
| 1 + 1 + 10 | 127 ± 51 | 102 ± 32 | 0.18 ± 0.03 | 0.17 ± 0.03 | 5.68 ± 0.02 | 5.66 ± 0.01 | |||
| 1 + 4 + 10 | 172 ± 32 | 134 ± 62 | 0.15 ± 0.01 | 0.14 ± 0.01 | 5.85 ± 0.01 | 5.85 ± 0.01 | |||
| 4 + 1 + 10 | 114 ± 63 | 77 ± 58 | 0.17 ± 0.03 | 0.16 ± 0.03 | 5.80 ± 0.01 | 5.80 ± 0.01 | |||
| Cefotaxime + morphine + aqNumeta G13E + | 1 + 1 + 1 | 241 ± 143 | 440 ± 156 | 0.09 ± 0.02 | 0.11 ± 0.03 | 5.74 ± 0.01 | 5.71 ± 0.02 | ||
| 1 + 2 + 20 | 362 ± 87 | 719 ± 282 | 0.16 ± 0.01 | 0.21 ± 0.07 | 5.81 ± 0.03 | 5.77 ± 0.01 | |||
| 9 + 1 + 2 | 1120 ± 662 | 678 ± 183 | 0.13 ± 0.04 | 0.15 ± 0.03 | 5.61 ± 0.01 | 5.60 ± 0.00 | |||
aResult is based on two parallels